吉利德科学在2025年第二季度的财务业绩显示，尽管整体营收仅增长2%，但其核心HIV业务表现强劲，特别是Biktarvy和Descovy销售额分别增长9%和35%。HIV产品销售额达51亿美元，占总营收的72%。然而，新冠药物Veklury和细胞疗法产品的销售持续下滑。公司上调了全年营收和盈利指引，并宣布了新的60亿美元股票回购计划，显示出对未来增长的信心。此外，FDA批准了吉利德新药...
Source Link吉利德科学在2025年第二季度的财务业绩显示，尽管整体营收仅增长2%，但其核心HIV业务表现强劲，特别是Biktarvy和Descovy销售额分别增长9%和35%。HIV产品销售额达51亿美元，占总营收的72%。然而，新冠药物Veklury和细胞疗法产品的销售持续下滑。公司上调了全年营收和盈利指引，并宣布了新的60亿美元股票回购计划，显示出对未来增长的信心。此外，FDA批准了吉利德新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.